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OBJECTIVES: To develop a symptom-based outcome
measure for asthma by measuring patient preferences
over asthma symptoms. METHODS: Asthma patients
were asked to choose between scenario pairs where each
scenario described the patient’s asthma symptoms over a
period of one week. Their responses to a series of such
choices were modelled using a random effects ordered
probit model. The particular symptoms considered were
daytime cough, daytime chest tightness, daytime wheeze,
daytime breathlessness, and sleep disturbance as a result
of night-time asthma symptoms. Questionnaires contain-
ing eight discrete choices were completed by 162 moder-
ate to severe asthma patients. RESULTS: The hypothesis
that patients weight the five symptoms equally was
clearly rejected. Specifically, daytime cough and breath-
lessness were weighted twice as heavily as the other three
symptoms. The weights did not appear to be influenced
by the patient’s age, gender, or asthma severity. There
was no evidence that the order in which symptoms were
presented affected the results. However, there was some
evidence that the conventional linear additive model may
not be suitable. CONCLUSIONS: Discrete choice model-
ling proved to be a useful approach for developing pref-
erence based outcome measures. There is considerable
scope and need for further refinement of the methods.
While the specific application reported concerned asthma
symptoms the general approach is potentially useful in a
wide range of applications.
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OBJECTIVES: Quality of life, lung function values, and
disease severity classification systems are frequently used
in clinical practice, clinical trials and in economic evalua-
tion of asthma treatment. However, the relationship
among these measurements is not well understood yet.
The objective of this study was to identify quality of life
values of asthmatic patients with different severity of dis-
ease based on the GINA severity classification system. To
examine the correlation between lung function values
(FEV1, PEF) and generic and disease-specific QoL mea-
surements. METHODS: 228 consecutive adult outpa-
tients and inpatients at four sites participated in the
study. Doctors had to classify the severity of disease and
report the latest measured FEV1 and PEF values. Patients
had to fill in three different quality of life questionnaires.
RESULTS: Mean quality of life values were 21, 38, 52,
60 for SGRQ questionnaire; 48, 43, 36, 31 for SF-36
(PCS); 55, 46, 42, 44 for SF-36 (MCS); 0.93, 0.76, 0.65,
0.52 for EuroQol weighted health status in the four se-
verity groups, respectively. Correlation coefficients were
0.62 between EuroQol and PCS; 0.59 between EuroQol
and MCS; 0.74 between SGRQ and PCS; 0.58 be-
tween SGRQ and MCS; 0.68 between SGRQ and Eu-
roQol. Correlation was 0.28, 0.37, 0.01, 0.21 be-
tween FEV1% and SGRQ, PCS, MCS, and EuroQol,
respectively. Similar values were gained in the case of
PEF% values. CONCLUSIONS: Lung function and QoL
values correlated less than medium strongly while differ-
ent QoL values correlated to each other stronger than
medium. Large differences were detected in QoL accord-
ing to disease severity. These results can be of high value
in modeling and burden of disease studies.
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OBJECTIVE: Prediction of future need for healthcare is
an essential component of pharmacoeconomic models.
However, recent developments in applied econometrics
have demonstrated the importance of investigating for
heterogeneity of risk within populations when using
count data (e.g. hospitalization). We tested the hypothe-
sis that there is a healthy sub-population with very low
risk of hospitalization amongst patients with Type 2 dia-
betes. METHODS: The study population comprised
4625 type 2 diabetic patients diagnosed before 1st Jan.
1993 and still alive until 31 Dec. 1995 in Tayside, Scot-
land. Number of hospitalizations for each patient was
calculated using a record linkage database. Risk factors
age, gender and previous hospitalization for cardiovascu-
lar diseases were obtained from the databases. We com-
pared Poisson, two-part Poisson, Negative binomial (NB)
and two-part NB models. The two-part models include a
logistic regression model as the first part and the trun-
cated Poisson or NB models as the second part. The max-
imum likelihood procedure was used to fit the models.
The likelihood ratio test and the Akaikes Information
Criterion were used for model comparison. RESULTS:
The best model was the two-part NB model. The risk fac-
tors associated with at least one hospitalization were age
(log-OR  0.0245, S.E.  0.0026) and previous hospi-
talization for MI (log-OR  0.5960, S.E.  0.1137),
Stroke (log-OR  0.7181, S.E.  0.1915) and other car-
